Hampel is enthusiastic about, if not totally endorsing, 2-73.
Hampel BELIEVES there are bodily functions which, if properly targeted, can address individual disease. I am wholeheartedly behind that hypothesis.
2-73 was shown to actually "enter" and affect S1. What that may come to mean is WHY we have trials.
I am happy Anavex is seen as relevant in Hampel's world. I look forward to the results from the process to determine EFFICACY of 2-73 and its other molecules.